Brief: OptiNose Inc - Reports Positive Top-Line Results In Reopen1, A Landmark Phase 3 Trial For Xhance In Chronic Sinusitis

OptiNose

07/03/2022 12:05

March 7 (Reuters) - OptiNose Inc  OPTN.O :
    * OPTINOSE INC - REPORTS POSITIVE TOP-LINE RESULTS IN
REOPEN1, A
LANDMARK PHASE 3 TRIAL FOR XHANCE IN CHRONIC SINUSITIS
    * OPTINOSE INC - XHANCE MET BOTH CO-PRIMARY ENDPOINTS IN
REOPEN1
TRIAL
    * OPTINOSE INC - EXPECTS TOP-LINE RESULTS FROM REOPEN2,
SECOND OF
ITS TWO PHASE 3 TRIALS FOR XHANCE IN CHRONIC SINUSITIS, IN THE
SECOND QUARTER OF 2022

Source text for Eikon:  ID: 
Further company coverage:  OPTN.O 

 ((Reuters.Briefs@thomsonreuters.com;))